Naarden Jacob Van Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 16 hours ago
Naarden Jacob Van has an estimated net worth of at least $12.8 million*, as of Aug. 13, 2025. They own 20,561 shares of LLY stock. They have sold 0 shares of LLY stock since 2021, for an estimated $0.
Naarden Jacob Van $LLY SEC Form 4 Insider Trading
Naarden Jacob Van has filed a total of 1 insider trades in $LLY since 2021. Their most recent trade was a purchase of 1,000 shares, made on Aug 13, 2025. Their largest trade was a purchase of 1,000 shares, made on Aug 13, 2025. We estimate that they now own 20,561 shares of $LLY, worth an estimated $12.8 million.
Insider Trading at $LLY
There have been a total of 696 insider trades reported at $LLY since 2021, with 7,130 shares purchased and 13.4 million shares sold. The most active insider traders in $LLY stock have been Donald A Zakrowski, Daniel Skovronsky, and Alonzo Weems. The most recent trade was a purchase of 758 shares reported by Ralph Alvarez (None), made on Aug 13, 2025.
History of Insider Stock Trades by Naarden Jacob Van
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
![]() |
Purchase | 1,000 | Aug 13, 2025 | Aug. 13, 2025, 4:15 p.m. |
$LLY Executives and Stock Owners with Insider Trades
-
Donald A Zakrowski, SVP, Finance, & CAO
-
Daniel Skovronsky, EVP, CSO & Pres. LRL & LLY Imm
-
Alonzo Weems, EVP, ERM & CECO
-
Donald A Zakrowski, Chief Accounting Officer
-
Johna Norton, EVP, Global Quality
-
Anne E. White, EVP & Pres, Lilly Neuroscience
-
Ilya Yuffa, SVP & President, LLY Int'l
-
Patrik Jonsson, SVP&Pres, LLY Imm, LLY USA&CCO
-
Alonzo Weems, SVP, ERM & CECO
-
David A Ricks, President, Chair, and CEO
-
Ilya Yuffa, EVP & President, LLY Int'l
-
Ilya Yuffa, EVP&Pres, LLY USA&Global Capab
-
Naarden Jacob Van, EVP & Pres., Lilly Oncology
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.